Drugs / Bedrocan
Bedrocan
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06334016 | Jul 2026 → Mar 2028 expected | cannabis dependence | Roswell Park Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04316598 | Mar → Jul 2020 | — | Parc de Salut Mar | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03813602 | Aug → Nov 2019 | psychiatric disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06159387 | Oct 2023 → Oct 2024 | cocaine dependence | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05235503 | Dec 2021 → Dec 2022 | respiratory underresponsiveness to hypoxia and hypercapnia, substance-related disorder | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05939466 | Mar → Sep 2021 | fibromyalgia | University of Basilicata | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bedrocan | “At t = 1.5 h and at t = 4.5 h the subject will inhale 100 mg Bedrocan.” NCT05235503 ↗ |
| Known as | Cannabis Sativa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03813602 ↗ |
| Known as | Cannabis sativa extract | “To evaluate the efficacy and safety of a Cannabis sativa extract (CBD (Cannabidiol) + up to 0.3% THC (Delta-9-tetrahydrocannabinol)), compared to placebo, in the treatment of...” NCT06159387 ↗ |
| Known as | Medicinal Cannabis | “The goal of this interventional study is to learn about the effect of Medicinal Cannabis (Bedrocan®) on Fibromyalgia patients with pain resistant to conventional therapy.” NCT05939466 ↗ |
| Route | Inhaled | “THC will be administered in the form of medical cannabis (Bedrocan®) inhaled by intrapulmonary route” NCT04316598 ↗ |